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ABSTRACT
Background
Individuals living with HIV/AIDS in sub-Saharan Africa generally take more than 90% of
prescribed doses of antiretroviral therapy (ART). This number exceeds the levels of adherence
observed in North America and dispels early scale-up concerns that adherence would be
inadequate in settings of extreme poverty. This paper offers an explanation and theoretical
model of ART adherence success based on the results of an ethnographic study in three sub-
Saharan African countries.
Methods and Findings
Determinants of ART adherence for HIV-infected persons in sub-Saharan Africa were
examined with ethnographic research methods. 414 in-person interviews were carried out with
252 persons taking ART, their treatment partners, and health care professionals at HIV
treatment sites in Jos, Nigeria; Dar es Salaam, Tanzania; and Mbarara, Uganda. 136 field
observations of clinic activities were also conducted. Data were examined using category
construction and interpretive approaches to analysis. Findings indicate that individuals taking
ART routinely overcome economic obstacles to ART adherence through a number of deliberate
strategies aimed at prioritizing adherence: borrowing and ‘‘begging’’ transport funds, making
‘‘impossible choices’’ to allocate resources in favor of treatment, and ‘‘doing without.’’
Prioritization of adherence is accomplished through resources and help made available by
treatment partners, other family members and friends, and health care providers. Helpers
expect adherence and make their expectations known, creating a responsibility on the part of
patients to adhere. Patients adhere to promote good will on the part of helpers, thereby
ensuring help will be available when future needs arise.
Conclusion
Adherence success in sub-Saharan Africa can be explained as a means of fulfilling social
responsibilities and thus preserving social capital in essential relationships.
The Editors’ Summary of this article follows the references.
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People living with HIV/AIDS in sub-Saharan Africa gen-
erally take more than 90% of prescribed doses of antiretro-
viral therapy (ART) [1–12]. This number exceeds the levels of
adherence observed in North America [13] and dispels early
scale-up concerns that adherence would be inadequate in
settings of extreme poverty [14–16].
These near-perfect levels of adherence are being achieved
despite formidable obstacles in the poorest regions of the
world. Prohibitive costs of self-pay medications and drug
stock-outs create insurmountable access barriers and lead to
missed doses [3,7,10,12,17–20]. Expanding access to free ART
and better distribution systems are addressing these ob-
stacles. However, out-of-pocket expenses, including user fees,
laboratory tests, and transportation over often long distances
to and from treatment sites remain important barriers to
sustained adherence and medical care [5,21–24]. Time spent
traveling to and attending clinical appointments places
additional economic strain on patients and their families by
competing with income generating activities. Failure to
negotiate economic obstacles can lead to ART interruptions,
viral rebound, and resistance to limited available regimens
[2,25].
Social and cultural obstacles also threaten adherence
success. Stigma and the fear of disclosure cause patients to
skip doses if privacy is unavailable at a scheduled dosing time
[5,21]. Conﬂicting messages from health care practitioners
and religious authorities may also interfere with adherence
[26,27]. Behavioral obstacles similar to those observed else-
where, including forgetting doses, fear of side effects,
traveling without medications, and stopping drugs when
symptoms disappear have also been reported for sub-Saharan
Africa [3,4,10,18,25,26].
Adherence facilitators in resource-scarce settings have
received less attention than adherence barriers. Currently,
home-based adherence ‘‘help’’ is emerging as an important
resource to support adherence. One form of home-based
help centers on community health workers. Community
health workers are laypersons trained and paid through
treatment programs to provide adherence support and other
services at home. They deliver medications, observe dosing,
refer individuals for HIV-testing, offer encouragement,
provide nutritional and housing support, help with trans-
portation, and in general represent important links between
clinics and communities [22,28–32].
A second form of home-based help is treatment supporters
[33]. Treatment supporters (also termed treatment ‘‘part-
ners’’ and treatment ‘‘assistants’’) are laypersons nominated
by patients to help with treatment adherence. They remind
patients of dosing times, and often (though not always)
witness dosing. They are not health care workers, but
individuals with close personal ties to patients. As family
members or friends, treatment supporters often live in the
same or a nearby household. Treatment supporters are not
speciﬁcally trained or paid, but nonetheless make a formal
commitment to their role. Early studies suggest that both
treatment support and community health worker approaches
to home-based help may improve treatment outcomes
[4,22,28,34].
More structured support in the form of clinic-based
modiﬁed directly observed therapy (MDOT) has shown
promising results in Kenya [35]. The factors accounting for
the observed beneﬁt of MDOT are currently unknown.
Results of similar initiatives in the United States are more
mixed [36,37].
To better understand exceptional adherence in sub-
Saharan Africa, we analyzed qualitative data from an ethno-
graphic study carried out in three countries: Nigeria,
Tanzania, and Uganda.
Methods
Study Design
This patient-centered ethnographic study took place in
public HIV-treatment settings in Nigeria, Tanzania, and
Uganda (see Table 1). The HIV/AIDS Clinic at Jos University
Teaching Hospital (JUTH) is located in a medium-sized city in
Nigeria’s central plateau and currently follows more than
8,400 patients prescribed ART. The ART Clinic of Amana
District Hospital is located in Dar es Salaam, Tanzania, and
currently follows approximately 5,300 patients on ART. The
Immune Suppression Syndrome (ISS) Clinic at Mbarara
University of Science and Technology is located in rural
southwest Uganda and currently follows approximately 7,000
patients prescribed ART. A wide range of geographic and
social variation is represented across the three sites.
Sampling
We used a purposeful sampling design. The goal of
purposeful sampling is to systematically represent a variety
of perspectives on the topic under study [38]. Three different
perspectives chosen for relevance to the topic of adherence
were represented in this research: (1) patients; (2) treatment
partners (termed ‘‘assistants’’ at the Tanzanian site); and (3)
health care providers. In Nigeria and Tanzania, random
samples of potential patient participants were drawn from
the larger populations of adults meeting inclusion criteria.
Inclusion criteria were: (1) age 18 y or older; (2) prescribed
antiretroviral therapy for HIV/AIDS for no fewer than 6 and
no more than 12 mo at the time of sampling; and (3)
residence within 20 km of Jos University Teaching Hospital
or Amana District Hospital. In Uganda, patient participants
were drawn from the larger Uganda Antiretroviral Treatment
Outcomes (UARTO) study, a prospective study of antiretro-
viral-naı ¨ve patients initiating ART led by one of the authors
(DRB).
Treatment partners who participated in the study were
referred by patient participants. Patients were asked to name
‘‘someone who assisted them in their efforts to take
antiretroviral medications.’’ Health care providers who
participated were volunteers who responded to a letter of
invitation introducing the study.
Recruitment
In Nigeria and Tanzania, patient participants were re-
cruited at the clinic during routine follow-up visits. At a free
moment (e.g., while waiting to be seen or at the conclusion of
the visit), staff approached eligible individuals to describe the
study and extend an invitation to participate. In Uganda,
permission to contact prospective patient participants for
recruitment was ﬁrst obtained by UARTO research staff.
Once permission was obtained, a research assistant for this
ethnographic study approached the participant for consent.
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Explaining Adherence Success in AfricaTreatment partners were visited or telephoned by staff
after giving permission for contact. Health care providers
who indicated interest in response to the letter of invitation
were invited to participate.
The research was approved by the institutional review
boards at Harvard Medical School (Boston, Massachusetts,
United States); Jos University Teaching Hospital (Jos, Niger-
ia); Muhimbili University of Health and Allied Sciences (Dar
es Salaam, Tanzania); Mbarara University of Science and
Technology (Mbarara, Uganda); and the Uganda National
Council for Science and Technology (Kampala, Uganda).
Written informed consent was obtained from all participants.
Data Collection
Data were collected through in-person qualitative inter-
views and observations of clinic activities. Information on
adherence was collected through the 3-d self-report instru-
ment from the AIDS Clinical Trials Group edited and
adapted for cultural context [39]. All data were collected by
African researchers. The researchers were Nigerians, Tanza-
nians, and Ugandans who had been trained in ethnographic
data collection techniques by two of the authors (NCW and
MAW).
In-Person Interviews
Multiple interviews were conducted with patient and
treatment partner participants to allow for elaboration of
areas whose signiﬁcance emerged as analysis proceeded. The
interviews were semistructured, meaning that predesignated
core topics, but not speciﬁc questions, were covered in each
session. This approach ensured that speciﬁc areas were
covered in each interview, but also allowed unanticipated
themes to emerge. Core topics for patient interviews
included: (1) speciﬁc experiences of taking ART (e.g.,
‘‘stories’’ of the most recent dose taken, most recent dose
missed); (2) clinic visits; (3) help received from treatment
partners. Core topics for treatment partner interviews
included: (1) types of help provided; (2) feelings about being
a treatment partner; (3) perceptions of the impact of help.
Core topics for health care provider interviews included: (1)
description of typical clinic visit; (2) the ways adherence
comes up in clinical visits; (3) perceptions of barriers to
adherence for patients.
The goal of the interviews was to understand ART
adherence from the interviewees’ points of view. Patient
participant and treatment partner interviews were conducted
in homes or at other locations of the interviewee’s choosing
outside the clinic. Health provider interviews were conducted
at the clinic. Privacy was protected by conducting the
interviews in locations where the conversation could not be
overheard. Interviewees had the option of conducting the
interview in the local language (Hausa, Kiswhahili, Runyan-
kore) or in English. Interviews were audio-recorded with
permission and averaged about an hour in length. Patients
received compensation in the form of reimbursement for
transportation (where applicable) or a small stipend.
Field Observations
Observations are a hallmark of ethnographic data collec-
tion. They involve the presence of a researcher in a natural-
istic setting and the witnessing of events and activities of
interest to a given research inquiry [40]. Observations have the
advantage of providing a direct view of phenomena under
study to complement one that is mediated through verbal
interview reports. The following activities were observed by
research staff at each of the clinical sites: (1) routine follow-up
visits of patients taking ART; (2) counseling sessions; (3) health
education sessions; and (4) the dispensing of antiretroviral
medications. Observation sessions lasted 30 min to 1 h.
Data Preparation
Shortly after the completion of each interview, the
interviewer produced a detailed write-up in English on the
interview content, using the audio-recording and notes taken
during the interview to ensure accuracy and completeness.
The interview write-ups took the form of ‘‘stream-lined’’
transcripts. A ‘‘stream-lined’’ transcript is produced in
English (without ﬁrst transcribing in the local language) and
consists only of interview questions asked and their
responses. This approach to data preparation has several
advantages. First and foremost, it captures the desired level of
detail often lost in a summary and preserves the exact words
of the interviewee. It can be completed in a reasonable
amount of time by the interviewer, eliminating the expense of
separate transcription. Accuracy is also improved using this
approach. The write-ups contain a section in which the
interviewer adds relevant contextual details and impressions
not captured in the transcript. Descriptions of activities
observed were written up following each session as ﬁeld
notes.
Data Analysis
Analysis aimed at explaining adherence to ART using an
inductive approach to category construction and interpreta-
tion of data [41,42]. Descriptive categories were constructed
to characterize approaches to overcoming economic ob-
stacles to care. To construct the categories, content related to
patients’ adherence experiences was retrieved from coded
data. Relevant sections of text were identiﬁed, copied, and
grouped according to the type of adherence obstacle
represented. These sections of text were then reread to
characterize the ways in which patients negotiated these
obstacles to avoid missing doses and clinic visits. The data
were re-organized in terms of these characterizations to
produce an initial category ‘‘set.’’ Each category forming the
set was named, deﬁned, and illustrated through interview
excerpts. The set was reﬁned—revised, speciﬁed, and elabo-
rated—through successive returns to the data in which
additional sections of relevant text were extracted. Interpre-
tive analysis used a theoretic social science construct to
develop an argument based on the categories. The data
suggested ‘‘social capital,’’ i.e., resources accruing from social
networks, as the best explanatory construct to interpret
adherence strategies and explain their success.
Results
Study Participants
158 patients, 45 treatment partners, and 49 health care
providers participated in this study. 414 interviews and 136
observation sessions were conducted across the three sites.
Characteristics of Study Participants
Patients. Approximately two-thirds (65%) of patients who
participated in this study were women. The mean age of the
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living with a partner. Approximately three-quarters (71%) of
the patients were Christian; the remainder were Muslim.
Primary school was the highest level of education completed
for slightly more than half (57%) of the patient sample. 65%
of patients met criteria for Stage III or Stage IV disease
according to World Health Organization (WHO) criteria at
initiation of HIV care.
Treatment partners. More than half (56%) of treatment
partners were female. The mean age of the group was 39 y.
Three-quarters (73%) were married or living with a partner.
60% were Christian; the remainder were Muslim. Primary
school was the highest level of education completed for about
a third (35%) of the group.
Health care providers. Approximately two-thirds (64%) of
health care provider participants were women, and the mean
age of the group was 38 y. About a quarter (27%) of the
sample were physicians; a third (35%) were nurses. Nineteen
percent were counselors and 16% were pharmacists or
medication dispensers. Two full-time ‘‘tracking’’ ofﬁcers,
responsible for locating patients lost to follow-up, were
included in the sample (2%), as was another expert patient
fulﬁlling an administrative function (1%).
Ethnographic Data
On the basis of category construction and interpretation of
the data, we organized the ﬁndings from ethnographic data to
demonstrate: (1) prioritization of adherence to overcome
economic obstacles, and (2) responsibility in social relation-
ships as an explanation of prioritization.
Prioritizing adherence to overcome economic obstacles.
Participants reported that most adherence obstacles were
related to resource scarcity. Resource scarcity means that
basic commodities required for daily living are not easily
available. For example, obtaining money for transportation
to clinic appointments (where prescriptions are reﬁlled) is
rarely a simple matter of dipping into a ready supply of cash.
Concerted effort and speciﬁc strategies were required to raise
needed funds to secure medications.
Patient participants spoke of raising transport funds
through loans and handouts, what they termed borrowing
and ‘‘begging.’’ Loans—from treatment partners and other
family and friends—were a reliable source of cash but were
expected to be repaid, often with interest. Some interviewees
reported selling possessions or earning income through work
to repay loans. Others borrowed repeatedly but saw no way to
resolve the debts they had incurred. Chronic indebtedness
was a source of considerable emotional distress for bor-
rowers, as these interview excerpts indicate: ‘‘Most times I
borrow money [to get to clinic] and worry about re-paying
the debt.’’ (Interviewer: ‘‘How do you re-pay the debts?’’) ‘‘I
work and look for money digging and weeding in people’s
plantations.’’ And: ‘‘When you do not have money you think
of how you will come to clinic for medicine. [Last time] I
borrowed from a friend but now I have paid it back.’’
(Interviewer: ‘‘How did you feel about borrowing?’’) ‘‘I felt raw
and depressed because I got worried. Actually I lost kilo-
grams. When I came to the clinic and got weighed I had lost 2
kgs.’’
Treatment partners reported borrowing to help patients.
In the following excerpt, a treatment partner describes how
‘‘having friends who have shops’’ provides access to credit
that enables her to accommodate the food preferences of the
patient she helps, who is not doing well: ‘‘The patient is
seriously sick now. She is not ok. And when patients are
seriously sick they lose their appetite. If you give her beans
she will not eat. So we are borrowing rice from people with
shops. They trust us and they lend, paying is a problem. I live
with good neighbors who have shops. They help me, and at
the end of the month I pay them. She likes rice very much. If
you cook rice with anything, she eats.’’
Requesting handouts of cash—termed ‘‘begging’’ by inter-
viewees—was also reported. Handouts were not expected to
be repaid. Interviewees ‘‘begged’’ handouts for transport
funds from family, friends, and health care providers: ‘‘If I see
the date [of clinic visit] is approaching, I will start begging for
help. I tell people the date of my clinic is coming and that I
don’t have money, so they should assist me.’’ And: ‘‘Some-
times I beg or ask for money to attend the clinic. Sometimes I
have money for going there and beg at the clinic [for money
to return]. Last time my uncle gave me money to go there. To
get back I had to beg for money from the doctor.’’
Cash in hand, whether borrowed, ‘‘begged,’’ or earned, is
immediately subject to competing claims. As a result, patient
participants were continually confronted with ‘‘impossible
choices’’: HIV care or treatment for a sick child? HIV care or
school fees? HIV care or food for the family? Resource
scarcity sometimes required denying the needs of loved ones
in order to secure money for transportation to clinic: ‘‘Seven
days before going to get the medicine, I try to look around for
money. If it means not eating or buying food for the children
I do that, because they told us that we are not supposed to
miss ...’’
Food, essential to survival and functional recovery while on
ART, was often treated as expendable. Patient participants
understood that taking medications with food and adhering
to a healthy diet that includes a variety of food groups is
important for their treatment and recovery on ART. Though
reluctant to ignore doctors’ orders, patient participants
sacriﬁced their own need for food to meet the needs of
others close to them: ‘‘If I don’t have porridge [when I take
the pills] I feel nauseated. [But at times it’s hard to get
porridge] because I buy it with money and when it’s the
school fee season there is no money.’’
Strategies for obtaining help from others notwithstanding,
there are times when patients simply ‘‘do without.’’ They do
without food, but take their medications anyway, despite
hunger-induced exacerbation of ART side effects. They do
without transport, and walk to clinic, which can often take
several hours: ‘‘It’s hard to take meds without food. When I
take meds without food I get a stomachache. But you can’t
miss meds because of food. I take meds with an expectation
that I may get food later.’’ And: ‘‘[When there’s no food] I just
take [the drugs] on an empty stomach. And I will feel like
vomiting – dizzy, weak and all. When I don’t eat before taking
drugs, honestly, I don’t ﬁnd it easy at all.’’ And: ‘‘Five months
ago the car got spoilt and now I am walking to the clinic. At
ﬁrst I had money for a [motorcycle taxi] but now I do not
even have that. I will continue walking whatever happens.’’
Borrowing and ‘‘begging’’ transport funds, making impos-
sible choices, and ‘‘doing without’’ are ways of overcoming
the economic obstacles that continue to block access to
treatment for HIV/AIDS despite the availability of free ART.
These sacriﬁces reﬂect the extraordinary efforts and commit-
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care: ‘‘Taking meds is my life. I have to give meds ﬁrst priority
because they are helping me.’’
Explaining prioritization: adherence to improve health and
fulﬁll responsibility in social relationships. As in resource-
rich settings, the immediate reason patients assign ‘‘ﬁrst
priority’’ to adherence is to improve health. Patient partic-
ipants described profound improvements after starting ART,
as grave illness gave way to weight gain, renewed energy and
strength, and the ability to care for themselves. With
treatment, most patients returned to normal activities,
including income-generation. Clinical improvement also
brought renewed hope for a long life. The restoration of
health and hope, together with the memory of previous
suffering and the threat of jeopardizing what has been gained
should adherence lapse, provide powerful motivation to take
ART correctly.
However, the pursuit of health does not completely explain
why patients assign ﬁrst priority to adherence. For African
patients, good health is important because it helps to
preserve relationships with others.
The contribution of social relationships to mental and
physical health is well-documented for North America [43–
47]. In settings of economic scarcity, relationships are not
only important for health but also essential to survival. Our
data suggest the prioritization of adherence reﬂects the
importance of relationships as a resource for managing
economic hardship.
Chronic illness is always hard on close relationships. But
when health care is a scarce resource, illness imposes an extra
burden on social intimates who must then assume responsi-
bility for care. Care provision means investing valuable time,
energy, and ﬁnancial resources to promote the patient’s
health. The investment is justiﬁed when there is an expect-
ation of recovery, but becomes harder to defend if it appears
the illness may be terminal. When an illness is considered
terminal, caregivers may look for ways of severing their
connection with the patient and ending the drain on scarce
resources. One interviewee explained it this way: ‘‘When I fell
sick, some of the people in my family thought I was going to
die soon, so they advised my brother and sister (whom I was
living with) to look for transport to send me back to the
village. Some people, if they see you in terminal illness, they
start to value their money. They think, ‘this illness is getting
worse. It’ll really cost me to transport a dead body, whereas to
arrange to transport a living body is different....’’’
Patient participants in this study received adherence
assistance from several sources. In addition to money for
transport, treatment partners, other family and friends, and
fellow patients provided regular reminders of dosing times.
They offered encouragement by emphasizing the beneﬁts of
treatment and continually reinforcing the importance of
taking medications as prescribed. Treatment supporters also
worked to destigmatize HIV/AIDS. They socialized in public
with infected persons; likened HIV/AIDS to common, but less
stigmatized conditions (e.g., malaria); and challenged myths
by deliberately sharing food and eating utensils. ‘‘...when
they [a set of friends of the patient] started understanding the
problem [HIV/AIDS], everybody started withdrawing from
eating in the same container with him. ...I saw everyone was
running away from him so I called him and lied to him. I did
not want to create division and break him the more. So I told
him, ‘look, I met one of your doctors and she told me that you
have to be very careful because of infection. You don’t eat
anything anybody else eats, you don’t use the same cup
anybody else uses, because you could get another infection
and it could be even worse.’ And then I ate with him, so the
others would see.’’
Health care providers were also important sources of help.
They supported adherence through education, reinforce-
ment, even the organization of care. At one site, providers
maintained a ﬂexible schedule to accommodate patients,
even though it made their days longer. They instituted a
policy of accepting ‘‘latecomers’’—individuals who arrived
after the deadline for being seen on a given day had passed.
Not infrequently, providers stepped outside their profes-
sional roles to make resources available to those in need.
They provided money and food at their own expense, and
organized larger efforts to generate support. In the following
quote, a provider describes her practice of helping indigent
women patients toward ﬁnancial independence by securing
small loans and then indicating how they might use the funds
to start small businesses: ‘‘I say, ‘go around in your area, your
community. Look at what people like that is not available
there. Go and get some of these things and begin to sell them.’
That is how I do it.’’
Providers expected adherence and did not hesitate to make
their expectations known. In clinic, staff communicated
expectations of adherence by stating repeatedly that anti-
retroviral therapy must be taken as prescribed. In extreme
cases, they even threatened those who repeatedly missed
clinic appointments with withdrawal of access, as we see from
the following report: ‘‘I told [the patient] this morning, ‘You
had better decide if you are going to take these drugs.
Because the way you are doing, you are creating resistance. I
am giving you my last warning. If you come next time with the
same story, even if you beg from heaven, we will discontinue
you.’ That is what I told her. (Interviewer: And would you
really?) If she comes back with the same story, I am serious.
We will discontinue her. We will.’’
Treatment partners also expected adherence. As one
person put it: ‘‘We insist she take her meds. We help her
because we want her to take her meds....If you don’t take
your meds, you will die.’’
Friends and family members taking responsibility for
someone’s well-being were sensitive to the fact that adher-
ence meant ‘‘doing well,’’ and ‘‘doing well’’ made their job
easier. They insisted on adherence as a gesture aimed at
reducing what one treatment partner termed the ‘‘work’’ of
care. He explained this way: ‘‘If he [patient] continues well,
the work of caring for him will be over. If he continues well, I
can visit him at the time I want. But if he is sick, I have to help
him so he will be okay and everyone else can continue with
their business. That’s why I insist, ‘my relative, don’t ignore
what they instruct you to do. If they tell you to take [ART] in
the morning and evening—do it! Don’t feel it is difﬁcult work
and don’t feel tired.’’’
Making a similar observation, someone else said: ‘‘[Before
the patient improved] it was difﬁcult. I had to be there all the
time. I kept the time for meds in my mind instead of him. I
was unable to go anywhere or do anything else before he
takes his meds. Now I’m free to do anything at any time
without having many thoughts.’’
Social expectations of adherence create obligations on the
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preserve relationships with helpers. By taking ART as
prescribed and ‘‘doing well,’’ patients reduce the burden of
help and acknowledge the work of care. This in turn fosters
continued good will on the part of helpers and reinforces the
likelihood that assistance will be available when future needs
arise. In settings of poverty, where ‘‘community safety nets’’
[48] replace public entitlements as resources for weathering
economic crises, the consistent good will of potential helpers
is required for survival.
Discussion
Our data point to economic obstacles and the strength of
social relationships as principal mediators of sustained
adherence in sub-Saharan Africa. These obstacles are being
routinely overcome through strategies aimed at prioritizing
adherence. Prioritization is accomplished with help from
others. The relationships that provide this assistance are a
critical resource not only for supporting adherence, but for
managing economic hardship more generally. In social
science, the use of relationships to obtain beneﬁts and
achieve desired ends has been termed ‘‘social capital.’’
In North America, adherence to ART for HIV/AIDS has
been interpreted as the product of information, motivation,
and behavioral skills operating at the individual level [49].
Such an interpretation depicts the individual as the primary
agent of behavior, and de-emphasizes social context.
As an analytic construct, social capital has been charac-
terized as a property of individuals and of organizations. It
has been used in the U.S. and Europe to examine the
dynamics of civic engagement [50], the accomplishment of
social action [51], and the production and reproduction of
inequalities [52]. The ingredients of social capital (trust,
cooperation, reciprocity, sociability) have been well-studied,
and care has been taken to distinguish social capital from
other forms of capital (e.g., economic, human, symbolic) [53].
Analysts agree on the characterization of social capital as a
resource grounded in networks of social relationships. We
deﬁne it as ‘‘resources accruing from a network of relation-
ships that help individuals to solve problems and get things
done.’’
The concept of social capital adds considerable explan-
atory power to the study of HIV/AIDS in sub-Saharan Africa.
It explains not only adherence success, but also the threat of
stigma. Stigma is feared because it leads to social isolation,
undermining relationships that are essential to survival.
Avoiding HIV-related stigma can be understood as an effort
to conserve social capital, a necessary resource in settings of
poverty.
Relationships confer responsibility in addition to provid-
ing resources. Recipients of help must recognize what they
receive and reciprocate. To ignore these responsibilities is to
risk resentment on the part of helpers. Adherence allows
patients to meet social responsibilities by preventing health
decline and reducing the need for support. This creates a
positive feedback loop in which social relationships help
patients overcome economic barriers to sustained adherence.
Adherence in turn fulﬁlls responsibilities to others. Recog-
nizing and fulﬁlling responsibilities to helpers through
adherence strengthens social relationships and ensures more
help will be available in the future.
Preservation of social capital lies at the heart of our
explanation, but we recognize inﬂuences in other domains.
These include: (1) social structure, e.g., patterns of inequality;
(2) infrastructure, e.g. weaknesses in health systems; (3)
culture, e.g., values, religious beliefs; and (4) individual
experience and behavior, e.g., side effects, lack of informa-
tion, psychological distress. We offer here a social relational
theory to explain adherence differences between resource-
rich and resource-poor settings, while acknowledging other
kinds of determinants that merit further study.
Qualitative analyses contribute to quantitative research in
medicine and public health by delineating useful constructs
and testable hypotheses. In detailing the explanatory power
of social capital, we point to its likely predictive value in
examining hypotheses such as: Greater social capital will be
associated with better ART access and adherence. Veriﬁca-
tion of such hypotheses will guide interventions to sustain
adherence and improve treatment effectiveness.
A question that immediately arises is whether the beneﬁts
of social capital are sustainable? How long can patients
realistically expect to receive resources from others who are
struggling with resource scarcity themselves? Social capital,
unlike many other forms of capital, increases with use [54].
However, while it may explain how economic obstacles to
adherence have been overcome to date, it leaves the
fundamental problem of poverty unaddressed. Caregiver
efforts to compensate for the effects of poverty are not a
substitute for affordable transportation, plentiful nutritious
food, clean water, adequate living situations, and accessible
and effective medical care. Eliminating underlying economic
obstacles will reduce the strain on relationships and thus help
to sustain both social capital and adherence.
We are not the ﬁrst to address the social dimensions of
adherence to ART in the context of international scale-up. A
call for a biosocial framing laid out general principles of a
socially grounded analysis and proposed relevant analytic
concepts—social capital among them [55]. The importance of
explaining adherence success in sub-Saharan Africa was
stated speciﬁcally in a more recent account, which offered
an anthropological history of treatment access and intro-
duced ‘‘therapeutic citizenship’’ as an explanatory construct
[56]. We propose an alternative construct emphasizing
interpersonal relations, and add supporting data.
There are several limitations to our ﬁndings. First, African
societies are highly heterogeneous. We collected data in
urban and rural settings in East and West Africa. However,
the extent to which these concepts explain adherence
behavior in other African contexts will be an important area
of future study. Second, we have developed a social
explanation but left other domains of inﬂuence unexplored.
As we develop theoretical models of adherence for resource-
scarce locations, these types of inﬂuences should be more
comprehensively represented. Third, while ART scale-up has
been highly successful, the dynamics of adherence will likely
evolve as patients confront long-term treatment. Finally, we
draw upon social capital as an explanatory construct, but stop
short of elaborating underlying cross-cultural differences in
deﬁnitions of personhood [57].
Conclusion
Like persons living with HIV/AIDS all over the world, sub-
Saharan Africans adhere to ART because they want to be
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explain adherence success. A more complete explanation
highlights the role of social capital in relationships as a
resource for prioritizing adherence and overcoming eco-
nomic obstacles to care. Adherence preserves social capital by
protecting relationships required for survival in settings of
poverty. This may be what patients are referring to when they
tell us they have ‘‘no choice’’ but to adhere.
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Editors’ Summary
Background. The acquired immunodeficiency syndrome (AIDS) epi-
demic has killed more than 25 million people since 1981, and about 30
million people (22 million in sub-Saharan Africa alone) are currently
infected with the human immunodeficiency virus (HIV), which causes
AIDS. HIV destroys immune system cells, leaving infected individuals
susceptible to other infections. Early in the AIDS epidemic, most HIV-
infected individuals died within ten years but in 1996, combination
antiretroviral therapy (ART)—a mixture of powerful drugs—was devel-
oped. For HIV-infected people living in affluent, developed countries,
HIV/AIDS became a chronic disease, but for the millions of infected
people living in low- and middle-income countries, HIV/AIDS remained a
death sentence—ART was simply too expensive. In 2003, this situation
was declared a global health emergency. Today, through the concerted
efforts of governments, international organizations, and funding bodies,
nearly one-third of the people in developing and transitional countries
who are in immediate need of life-saving ART receive free, reliable
supplies of the drugs they need.
Why Was This Study Done? For ART to work, it must be taken regularly.
If drug doses are missed, the virus can rebound and resistance to ART is
more likely to develop. In poor countries, even though free antiretroviral
drugs are increasingly available, many obstacles to good adherence to
ART remain. These include economic obstacles (for example, the cost of
traveling to clinics and the loss of earning associated with clinic
attendance), and social, cultural, and behavioral barriers. Some patients
fear disclosure, for example. Others receive conflicting messages about
the benefits of ART. However, despite worries that the scale-up of ART
provision in developing countries would be dogged by inadequate
adherence, people living with HIV/AIDS in sub-Saharan Africa generally
take more than 90% of their prescribed doses of ART, a better level of
adherence than in North America. In this study, the researchers
investigate why ART adherence is so high in sub-Saharan Africa by
analyzing qualitative data from an ethnographic study done in Nigeria,
Tanzania, and Uganda. Qualitative data are often used to address ‘‘how’’
and ‘‘why’’ research questions: ethnography is a comprehensive
qualitative approach to describing and explaining human behavior and
culture.
What Did the Researchers Do and Find? For their study, the
researchers interviewed 158 patients, 45 treatment partners (lay-people
who help HIV-positive people keep to their treatment), and 49 health
care workers. Patients were asked about their experiences of ART and
about the help they received from their treatment partners; partners
were asked about the type of help they gave and about their feelings
about this help; health care workers were asked to describe a typical
clinic visit and to indicate how adherence was discussed. From these
interviews and observations of clinic sessions, the researchers identified
several strategies used by patients and their treatment partners to
overcome economic obstacles to ART adherence. These included
borrowing and ‘‘begging’’ funds to pay for travel to clinics and making
‘‘impossible choices’’ to prioritize adherence, and ‘‘doing without.’’ The
researchers’ analysis also indicates that the prioritization of adherence to
ART reflects the importance of relationships as a resource for managing
economic hardship. So, for example, they found that treatment partners
and health care workers expected patients to adhere to ART (which, by
improving patients’ health, improves their ability to support themselves
and their families) and made their expectations known, thereby creating
a responsibility among patients to adhere. Patients, in turn, adhered to
their treatment to promote good will from their helpers and thus ensure
their continuing help.
What Do These Findings Mean? The findings offer a possible
explanation of adherence success in sub-Saharan Africa. The high level
of adherence to ART can be explained as a means of fulfilling social
responsibilities. Adherence, the researchers suggest, not only improves
personal health (the main driver for ART adherence in resource-rich
environments) but also preserves ‘‘social capital’’ in essential relation-
ships. In other words, in sub-Saharan Africa, adherence to treatment may
protect the relationships that individuals living in extreme poverty rely
on to help them survive.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000011.
  This study is further discussed in a PLoS Medicine Perspective by Agnes
Binagwaho and Niloo Ratnayake
  Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
  HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including an article about to antiretroviral therapy
  Information is available from Avert, an international AIDS charity, on
HIV and AIDS in Africa (including detailed information on HIV/AIDS in
Nigeria and Uganda) and on providing AIDS drug treatment for
millions
  The World Health Organization provides information about universal
access to HIV treatment (in several languages)
  The US Centers for Disease Control and Prevention also provides
information on global efforts to deal with the HIV/AIDS pandemic
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